SureTrader SureTrader
Home > Boards > US Listed > Biotechs >

Merrimack Pharmaceuticals, Inc. (MACK)

Add MACK Price Alert      Hide Sticky   Hide Intro
Moderator: $Pistol Pete$
Search This Board:
Last Post: 11/23/2016 12:51:13 AM - Followers: 54 - Board type: Free - Posts Today: 0

Welcome to Merrimack Pharmaceuticals, Inc. (MACK) Board!!!

At Merrimack, researchers, clinicians, professionals, and, yes, engineers work together in a multidisciplinary, team-based environment. All are committed to a single vision. Building cures for cancer.


       Our Leadership

           Robert J. Mulroy has served as our President and Chief Executive Officer and a member of our board of directors since May 1999. Prior to joining us, Mr. Mulroy worked as a management consultant in the pharmaceutical and healthcare                  industries. Mr. Mulroy has also worked as a consultant in the field of international development and has served as an advisor to multiple start-up companies in the biotechnology industry. Mr. Mulroy holds a master’s degree in public and                    private  management from Yale University and a BA from Stanford University.

           Yasir B. Al-Wakeel, BM BCh, has served as our Chief Financial Officer and Head of Corporate Development since August 2015. Dr. Al-Wakeel previously served in various capacities at Credit Suisse, an investment bank, from January 2008            to June 2015. While at Credit Suisse, Dr. Al-Wakeel was most recently a Director of Healthcare Investment Banking focused on biotechnology and, prior to that role, he was an Equity Research Analyst covering the biotechnology and                        specialty pharmaceuticals sectors. Before joining Credit Suisse, Dr. Al-Wakeel was a practicing physician, holding both clinical and academic medical posts. Dr. Al-Wakeel holds a BM BCh (Doctor of Medicine) from Oxford University, an MA            in theology from Cambridge University and a BA from Cambridge University.

           Peter N. Laivins has served as our Head of Development since May 2014. Mr. Laivins served as our Vice President of Clinical Development from October 2011 to May 2014. Previously, Mr. Laivins ran an independent consulting practice                  specializing in oncology and neuroscience from January 2010 to October 2011. Prior to that, Mr. Laivins served as Vice President of Strategic Marketing at Elan Corporation, plc, a biopharmaceutical company, from 2006 to January 2010.                Mr. Laivins began his career at Pfizer Canada, joined Pfizer International in New York in 1995 and held positions of increasing responsibility at Pfizer Inc., culminating as Group Leader of Pfizer US Oncology Marketing until 2006. Mr. Laivins            holds an  MBA and a BS from McGill University.

           Gavin MacBeath, PhD, is a founder of Merrimack and Head of Translational Medicine. Dr. MacBeath leads translational research and drives our innovative diagnostic programs, helping to ensure we get the right drug to the right patient at                the right time. He is also a founder of Chestnut Pharmaceuticals, serves on the Scientific Advisory Board of Aushon Biosciences and is a Lecturer and Principal Investigator at Harvard Medical School. He joined Merrimack in 2009 after                    serving on the  faculty in the Department of Chemistry and Chemical Biology at Harvard University for eight years where he focused on developing and applying protein microarray technology to facilitate basic research in the area of systems            biology. Dr. MacBeath holds a Bachelors of Science from University of Manitoba, Canada, and a PhD in Macromolecular and Cellular Structure and Chemistry from The Scripps Research Institute in La Jolla, California.

           William M. McClements has served as our Head of Corporate Operations since September 2011. Previously, Mr. McClements served as Chief Human Resources Officer of Integreon Managed Solutions, Inc., a global research and business            services company, from May 2010 to September 2011. Prior to that, Mr. McClements served as Chief Operating Officer and a partner at Monitor Group, a global strategic advisory firm, where he worked from 1987 to May 2010. From                        September 2009 to March 2010, Mr. McClements also served as Acting President of Be the Change, Inc., a nonprofit focused on creating national issue-based campaigns. Mr. McClements holds an MBA from Harvard Business School and              a BA from Williams College.

           Birgit M. Schoeberl, PhD, has served as our Head of Discovery since January 2015. Dr. Schoeberl served as our Senior Vice President of Research from January 2014 to January 2015, as our Vice President of Research from October 2009            to January 2014 and in various other research roles since she joined us in 2003. Prior to joining us, Dr. Schoeberl was a post-doctoral fellow at the Massachusetts Institute of Technology, where she built some of the earliest computational                models of  signaling networks. Dr. Schoeberl holds a PhD in systems biology from the Max Planck Institute for Dynamics of Complex Technical Systems in Germany and an MS in chemical engineering from the University of Karlsruhe in                  Germany.

           Edward J. Stewart has served as our Head of Commercial since December 2011. Mr. Stewart served as our Senior Vice President of Business Development from March 2009 to December 2011 and in various other business development                roles since he joined us in 2001. Mr. Stewart began his career at KPMG Peat Marwick LLP in the life sciences strategy consulting group. Mr. Stewart holds an MBA from the Johnson Graduate School of Management at Cornell University                and a BS from  Bates College.

          William A. Sullivan has served as our Head of Finance and Accounting since August 2015 and our Treasurer since February 2010. Mr. Sullivan served as our Chief Financial Officer from May 2011 to August 2015, as our Vice President of               Finance from February 2010 to May 2011, and as our Controller from November 2007 to February 2010. Previously, Mr. Sullivan served as Corporate Controller of Vette Corp., a thermal management solutions company, from 2004 to 2007.             Mr. Sullivan began his career at Arthur Andersen LLP, where he obtained his certified public accountant license. Mr. Sullivan holds an MBA and an MS in accounting from Northeastern University’s Graduate School of Professional                             Accounting and a BA from Williams College.

     Contact Us

        One Kendall Square
        Building 700, Suite B7201
        Cambridge, MA 02139
        Phone: 617-441-1000



  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
MACK News: Quarterly Report (10-q) 11/09/2016 05:23:00 PM
MACK News: Current Report Filing (8-k) 11/09/2016 04:09:56 PM
MACK News: Merrimack Reports Third Quarter 2016 Financial Results 11/09/2016 04:02:00 PM
MACK News: Merrimack Announces Timing of Third Quarter 2016 Investor Conference Call 11/02/2016 04:15:00 PM
MACK News: Merrimack Announces Acceptance for Review of ANDA filed by Actavis for Generic Doxorubicin Hydrochloride Liposome Injection (... 10/31/2016 07:30:00 AM
#436  Sticky Note $MACK ~ Merrimack Pharmaceuticals, Inc. due diligence re $Pistol Pete$ 10/26/15 05:04:22 PM
#476   $MACK Merrimack Announces Acceptance for Review of ANDA $Pistol Pete$ 11/23/16 12:51:13 AM
#475   MACK News: Merrimack Announces Acceptance for Review of mick 11/01/16 01:36:25 AM
#474   Merrimack Pharmaceut (MACK) mick 11/01/16 01:36:18 AM
#473   $MACK Technical Analysis $Pistol Pete$ 10/19/16 09:03:48 PM
#472   >>Gap closed. Heading up.<< Protocola 10/12/16 03:42:55 PM
#471   Gap closed. Heading up. INTL 10/11/16 10:06:46 AM
#470   Unfortunately, for that options sharpy, MACK is trending Protocola 10/03/16 04:57:10 PM
#469   grab em while they are cheap mikekrane 10/03/16 07:59:31 AM
#468   I agree, looks like somebody is expecting something 808Options 10/02/16 11:54:01 PM
#467   MACK romanov5 10/01/16 09:04:08 PM
#466   * * $MACK Video Chart 09-22-16 * * ClayTrader 09/22/16 05:09:27 PM
#465   Nice close Go $MACK $Pistol Pete$ 09/21/16 04:26:01 PM
#464   $MACK $Pistol Pete$ 09/02/16 09:32:52 PM
#463   Watching for entry T695 08/25/16 12:33:45 AM
#462   $MACK Daily Chart $Pistol Pete$ 08/21/16 08:35:37 PM
#461   Mariner Investment Group LLC held its position in Mitshu35 08/03/16 08:41:28 PM
#460   MACK good change of a squeeze here... Lot clydesur 08/03/16 02:34:18 PM
#459   After doing a lot of dd, it's clear faxedreceipts 08/02/16 11:57:27 AM
#458   Nice write up on MACK by Bret Jensen Mitshu35 08/02/16 11:34:25 AM
#457   $MACK $Pistol Pete$ 08/02/16 12:22:25 AM
#456   Reddit ARTICLE: Mitshu35 08/01/16 02:33:12 PM
#455   $MACK Daily and Weekly Charts http://www.stock $Pistol Pete$ 07/04/16 08:42:51 AM
#454   $MACK Daily Chart $Pistol Pete$ 05/08/16 07:51:44 PM
#453   $MACK is a BUY with 106.1% upside to jones99 05/04/16 06:52:04 AM
#452   $MACK Ichimoku Daily & Weekly Chart w/Accum Line [i $Pistol Pete$ 04/19/16 11:38:24 PM
#451   $MACK Daily Chart $Pistol Pete$ 04/13/16 01:24:14 AM
#450   $MACK Daily and Weekly Charts http://www.stock $Pistol Pete$ 03/19/16 11:03:14 PM
#449   $MACK Daily and Weekly Charts http://www.stock $Pistol Pete$ 01/25/16 10:36:56 PM
#448   $MACK Daily Chart $Pistol Pete$ 01/10/16 10:59:56 PM
#447   Thank u $Pistol Pete$ 01/08/16 09:46:01 AM
#446   Yep, they're marketing and developing it on their tpizzazz24 01/08/16 06:26:30 AM
#445   Yep, they're marketing and developing it on their tpizzazz24 01/08/16 06:26:30 AM
#444   I think the Drug is in US $Pistol Pete$ 01/05/16 08:21:19 PM
#443   I have a question about ONIVYDE. Are they tpizzazz24 12/24/15 12:57:12 PM
#442   $MACK Daily and Weekly Chart htt $Pistol Pete$ 12/08/15 07:07:24 PM
#441   $MACK Daily & Weekly Chart http://stock $Pistol Pete$ 11/27/15 09:16:20 PM
#440   $MACK Daily & Weekly Chart http://stockcharts $Pistol Pete$ 11/09/15 07:04:26 PM
#439   Sold. Waiting for financials next Monday to potentially BigGreen101 11/03/15 09:54:16 AM
#438   Looks like it Go $MACK $Pistol Pete$ 10/29/15 05:55:29 PM
#437   Some pull back today. Friday may be BigGreen101 10/29/15 04:34:32 PM
#436   $MACK ~ Merrimack Pharmaceuticals, Inc. due diligence re $Pistol Pete$ 10/26/15 05:04:22 PM
#435   $MACK myopinion 10/26/15 04:38:33 PM
#434 mick 10/26/15 03:05:07 PM
#433   $MACK Weekly Chart http://stockcharts.c $Pistol Pete$ 10/26/15 01:43:51 PM
#432   $MACK Daily Chart For Review http://sto $Pistol Pete$ 10/26/15 01:41:32 PM
#431   $MACK Merrimack Announces U.S. FDA Approval of ONIVYDE™ $Pistol Pete$ 10/26/15 01:39:45 PM
#430   Nice DD Go $MACK $Pistol Pete$ 10/26/15 01:38:56 PM
#429   Merrimack Pharmaceut (MACK) mick 10/26/15 01:20:21 PM
#428   Yes. This happened with several biotechs that I BigGreen101 10/23/15 08:56:03 AM
#427   Black label box did it. Was halted at fourdueces 10/22/15 05:51:32 PM